Literature DB >> 11983240

Past, present and future of HIV vaccine trials in developing countries.

José Esparza1, Saladin Osmanov, Claire Pattou-Markovic, Coumba Touré, Marie Louise Chang, Stephanie Nixon.   

Abstract

A safe, effective and accessible preventive vaccine is our best long-term hope for the control of the HIV/AIDS pandemic. The first phase I trial of an HIV vaccine was conducted in the US in 1987. Since then, >30 candidate vaccines have been tested in over 60 phase I/II clinical trials, involving >8000 healthy human volunteers. The majority of these trials have been conducted in the US and Europe, however, trials have also been conducted in developing countries (Brazil, China, Cuba, Haiti, Kenya, Thailand, and Uganda), including an ongoing phase III efficacy trial of a rgp120 candidate vaccine in Thailand. The effort to develop and evaluate HIV vaccines must increase, especially in Africa.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11983240     DOI: 10.1016/s0264-410x(02)00062-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Scaling up human papillomavirus vaccination: a conceptual framework of vaccine adherence.

Authors:  Ingrid T Katz; Norma C Ware; Glenda Gray; Jessica E Haberer; Claude A Mellins; David R Bangsberg
Journal:  Sex Health       Date:  2010-09       Impact factor: 2.706

2.  Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope.

Authors:  N A Doria-Rose; G H Learn; A G Rodrigo; D C Nickle; F Li; M Mahalanabis; M T Hensel; S McLaughlin; P F Edmonson; D Montefiori; S W Barnett; N L Haigwood; J I Mullins
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

3.  A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity.

Authors:  Kenji Someya; Ke-Qin Xin; Kazuhiro Matsuo; Kenji Okuda; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

4.  Future HIV vaccine acceptability among young adults in South Africa.

Authors:  Jennifer N Sayles; Catherine L Macphail; Peter A Newman; William E Cunningham
Journal:  Health Educ Behav       Date:  2009-06-09

5.  Willingness of Chinese injection drug users to participate in HIV vaccine trials.

Authors:  Lu Yin; Yuanzhi Zhang; Han-Zhu Qian; Baoling Rui; Lijiang Zhang; Junling Zhu; Yongsheng Guan; Yunxia Wang; Qingchun Li; Yuhua Ruan; Yiming Shao
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

6.  Reasons for declining to enroll in a phase I and II HIV vaccine trial after randomization among eligible volunteers in Dar es Salaam, Tanzania.

Authors:  Edith A M Tarimo; Anna Thorson; Thecla W Kohi; Muhammad Bakari; Fred Mhalu; Asli Kulane
Journal:  PLoS One       Date:  2011-02-16       Impact factor: 3.240

Review 7.  Framing the social in biomedical HIV prevention trials: a 20-year retrospective.

Authors:  Kathleen M MacQueen
Journal:  J Int AIDS Soc       Date:  2011-09-27       Impact factor: 5.396

8.  In/dependent Collaborations: Perceptions and Experiences of African Scientists in Transnational HIV Research.

Authors:  Ferdinand Moyi Okwaro; P W Geissler
Journal:  Med Anthropol Q       Date:  2015-05-14

9.  Declining HIV-1 prevalence and incidence among Police Officers - a potential cohort for HIV vaccine trials, in Dar es Salaam, Tanzania.

Authors:  Patricia J Munseri; Muhammad Bakari; Mohamed Janabi; Eric Aris; Said Aboud; Bo Hejdeman; Eric Sandstrom
Journal:  BMC Public Health       Date:  2013-08-06       Impact factor: 3.295

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.